MedTrace Logo

Cannabidiol Effects on Fear Extinction in Social Phobia

NCT06123702 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-04-19

No results posted yet for this study

Summary

The investigators will randomly assign participants with social anxiety disorder to receive oral cannabidiol (CBD) or placebo. Participants will undergo a fear conditioning and extinction trial, and the investigators will examine whether CBD increases the degree of fear reduction during extinction.

Conditions

Interventions

BEHAVIORAL

Fear extinction

Extinction of conditioned fear response

DRUG

Cannabidiol Cap/Tab

12 50-mg capsules

DRUG

Placebo

12 placebo capsules

Sponsors & Collaborators

  • Hartford Hospital

    lead OTHER

Principal Investigators

  • David Tolin, Ph.D. · Hartford Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06123702 on ClinicalTrials.gov